Zevra Therapeutics (NASDAQ:ZVRA) Trading Down 10%

Zevra Therapeutics, Inc. (NASDAQ:ZVRA – Get Rating) shares were down 10% on Tuesday . The company traded as low as $4.41 and last traded at $4.43. Approximately 351,489 shares were traded during mid-day trading, an increase of 51% from the average daily volume of 233,420 shares. The stock had previously closed at $4.92.

Wall Street Analysts Forecast Growth

Separately, Maxim Group started coverage on shares of Zevra Therapeutics in a research report on Friday, March 17th. They set a “buy” rating and a $12.00 price objective on the stock.

Zevra Therapeutics Trading Down 10.0 %

The company has a 50 day simple moving average of $5.31. The firm has a market capitalization of $153.01 million, a price-to-earnings ratio of -3.69 and a beta of 2.21. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.93 and a quick ratio of 7.93.

Insider Activity at Zevra Therapeutics

In related news, CEO Richard W. Pascoe bought 10,000 shares of the company’s stock in a transaction on Thursday, March 9th. The shares were bought at an average price of $4.20 per share, with a total value of $42,000.00. Following the transaction, the chief executive officer now owns 29,973 shares in the company, valued at $125,886.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Matthew R. Plooster acquired 11,000 shares of the company’s stock in a transaction that occurred on Thursday, March 9th. The stock was purchased at an average price of $4.20 per share, with a total value of $46,200.00. Following the completion of the acquisition, the director now owns 18,500 shares of the company’s stock, valued at approximately $77,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Richard W. Pascoe purchased 10,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, March 9th. The shares were acquired at an average cost of $4.20 per share, for a total transaction of $42,000.00. Following the transaction, the chief executive officer now directly owns 29,973 shares of the company’s stock, valued at approximately $125,886.60. The disclosure for this purchase can be found here. Insiders purchased 26,444 shares of company stock worth $112,048 in the last 90 days. 1.10% of the stock is owned by corporate insiders.

Zevra Therapeutics Company Profile

(Get Rating)

Zevra Therapeutics, Inc is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy.